Pipeline

Clinical Pipeline


Shattuck’s lead partnered compound entered the clinic in April 2019, and its lead wholly-owned compound entered the clinic in August of 2020.

To date, Shattuck’s Agonist Redirected Checkpoint (ARC) platform has yielded more than 300 bi-functional fusion protein drug candidates, two of which are currently in clinical trials for the treatment of life-threatening and debilitating diseases. The two lead ARC molecules are designed to block checkpoint molecules that limit the immune system (PD-1 and CD47) while simultaneously stimulating T-cell receptors to initiate an immune response (OX40 or CD40). Shattuck’s lead partnered asset, SL-279252 (PD1-Fc-OX40L), has advanced to the clinic in less than two years and is currently enrolling patients at five sites across the United States, Canada, and Europe. Shattuck’s internal lead asset, SL-172154 (SIRPα-Fc-CD40L), began enrolling patients in its clinical trials during the second half of 2020.

PlatformProgramDomain 1Domain 2IndicationsDiscoveryPreclinicalPhase 1Phase 2Phase 3Anticipated Milestones / Status
Clinical-Stage Pipeline
ARCSL-172154SIRPαCD40LOvarian Cancer

Initial Dose Escalation Data 2H'2021

ARCSL-172154SIRPαCD40LCSCC and HNSCC(1)

Initial Dose Escalation Data 1H'2022

ARCSL-279252PD-1OX40LAdvanced Solid Tumors and Lymphoma

Dose Escalation Data 2H'2021

Select Preclinical-Stage Pipeline
ARCSL-115154CSF1RCD40LAdvanced Solid Tumors

Manufacturing

ARCSL-9258TIGITLIGHTOncology

Manufacturing

ARCSL-279137PD-14-1BBLOncology

Non-Clinical Dev.

ARCSL-6159CD86NKG2aOncology

Lead Selection

ARCMultipleUndisclosedUndisclosedAutoimmune

Lead Selection

GADLENMultipleγδ TCRTumor AntigenOncology

Lead Candidate Selection 2021

DrugIndicationStage
SL-172154Ovarian Cancer Phase 1
SL-172154CSCC and HNSCC(1) Phase 1
SL-279252Advanced Solid Tumors and Lymphoma Phase 1
SL-115154Advanced Solid Tumors Preclinical
SL-9258Oncology Preclinical
SL-279137Oncology Preclinical
SL-6159Oncology Discovery
MultipleAutoimmune Discovery
MultipleOncology Discovery

(1)  Cutaneous Squamous Cell Carcinoma (CSCC) and Head and Neck Squamous Cell Carcinoma (HNSCC)
   Takeda holds exclusive options to license SL-279252 and SL-115154